Index
RUT
Market Cap
3.39B
Enterprise Value
4.38B
Income
52.00M
Sales
1.84B
Book/sh
40.84
Cash/sh
10.63
Employees
2900
IPO
May 08, 1950
P/E
65.52
Forward P/E
17.23
PEG
1.27
P/S
1.84
P/B
1.81
P/C
6.96
P/FCF
13.68
EV/EBITDA
11.47
EV/Sales
2.38
Quick Ratio
1.89
Current Ratio
3.05
Debt/Eq
0.79
LT Debt/Eq
0.78
Option/Short
Yes / Yes
EPS (ttm)
1.13
EPS next Y
4.30
EPS next Q
1.27
EPS this Y
3.56%
EPS next Y
22.79%
EPS next 5Y
13.53%
EPS past 3/5Y
-95.12% -15.51%
Sales past 3/5Y
-8.63% -1.98%
EPS Y/Y TTM
106.07%
Sales Y/Y TTM
-1.39%
EPS Q/Q
102.16%
Sales Q/Q
7.34%
Insider Own
1.29%
Insider Trans
0.00%
Inst Own
116.10%
Inst Trans
2.69%
ROA
1.63%
ROE
3.99%
ROIC
1.56%
Gross Margin
26.59%
Oper. Margin
8.57%
Profit Margin
2.82%
SMA20
2.44%
SMA50
3.58%
SMA200
16.01%
Trades
Shs Outstand
45.79M
Shs Float
45.20M
52W High
78.25 -5.35%
52W Low
47.12 57.18%
Volatility
2.07% 2.24%
ATR (14)
1.70
RSI (14)
61.74
Beta
0.36
Rel Volume
0.64
Avg Volume
596.51K
Volume
229,629
Perf Week
1.77%
Perf Month
7.68%
Perf Quarter
3.30%
Perf Half Y
41.72%
Perf YTD
26.24%
Perf Year
53.57%
Perf 3Y
-4.56%
Perf 5Y
-24.26%
Perf 10Y
34.90%
Prev Close
74.19
Price
74.07
Change %
-0.17%
Analysts 12 incl. previous ratings
Rating Distribution 8 Buy · 4 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside May 06, 2026 Upgrade S Seaport Research Partners
Neutral → Buy $75 +1.3% Dec 15, 2025 Upgrade B BMO Capital Markets
Market Perform → Outperform $71 -4.1% Sep 08, 2025 Initiated M Morgan Stanley
Equal-Weight $60 -19.0% May 01, 2025 Downgrade W Wells Fargo
Overweight → Equal Weight Mar 26, 2025 Upgrade J JP Morgan
Neutral → Overweight $68 → $71 -4.1% Mar 05, 2025 Downgrade S Seaport Research Partners
Buy → Neutral Aug 08, 2024 Upgrade J JP Morgan
Underweight → Neutral $90 → $89 +20.2% Apr 11, 2024 Upgrade W Wells Fargo
Equal Weight → Overweight $100 → $112 +51.2% Mar 14, 2024 Upgrade J Jefferies
Hold → Buy $100 → $126 +70.1% Mar 01, 2024 Initiated W Wolfe Research
Outperform $108 +45.8% Jun 29, 2023 Downgrade E Evercore ISI
Outperform → In-line Jun 26, 2023 Downgrade B BMO Capital Markets
Outperform → Market Perform $109 → $90 +21.5% Feb 02, 2023 Downgrade J JP Morgan
Neutral → Underweight $104 → $105 +41.8% Sep 12, 2022 Initiated C Credit Suisse
Outperform $120 +62.0% Jan 20, 2022 Downgrade W Wells Fargo
Overweight → Equal Weight $120 → $110 +48.5% Nov 11, 2021 Downgrade M Monness Crespi & Hardt
Buy → Neutral Oct 13, 2021 Initiated M Mizuho
Buy $116 +56.6% Jul 30, 2021 Upgrade J JP Morgan
Underweight → Neutral $90 +21.5% Jun 18, 2021 Initiated S Stifel
Buy $118 +59.3% May 04, 2021 Downgrade J JP Morgan
Neutral → Underweight $88 → $89 +20.2%
Show Previous Ratings
Oct-27-26 07:00AM
Oct-26-26 07:16PM
Sep-22-26 07:00AM
Sep-14-26 07:00AM
Aug-31-26 06:30PM
07:00AM
Loading…
Aug-24-26 07:00AM
Aug-07-26 05:00PM
Jul-29-26 05:00PM
Jul-28-26 05:22PM
05:01PM
05:00PM
Jul-14-26 05:01PM
Jul-08-26 07:38AM
Jun-29-26 04:30PM
Jun-10-26 06:07PM
04:05PM
Loading…
Jun-09-26 04:05PM
May-22-26 06:23PM
May-18-26 07:00AM
May-15-26 06:23PM
May-05-26 05:01PM
Apr-28-26 05:13PM
(Associated Press)
-13.77%
05:01PM
Apr-15-26 05:01PM
Mar-23-26 06:55AM
Mar-17-26 05:01PM
Mar-04-26 11:30AM
Feb-20-26 12:41PM
Feb-10-26 11:01AM
Feb-09-26 07:00AM
Feb-03-26 06:07PM
04:00PM
Loading…
04:00PM
07:05AM
Feb-02-26 06:30PM
06:15PM
05:13PM
(Associated Press Finance)
05:01PM
Jan-29-26 06:15PM
10:00AM
Jan-27-26 07:02AM
Jan-20-26 05:01PM
Jan-19-26 05:01PM
Jan-05-26 08:09AM
Dec-15-25 09:16AM
Dec-05-25 06:35PM
Dec-04-25 11:30AM
Dec-03-25 12:27PM
Dec-01-25 04:34PM
Nov-19-25 05:01PM
Nov-06-25 07:12AM
Nov-05-25 04:05PM
Nov-04-25 07:30PM
06:35PM
05:46PM
(Associated Press Finance)
05:01PM
07:49AM
Nov-03-25 07:34AM
Oct-30-25 05:01PM
Oct-28-25 10:00AM
Oct-23-25 07:00AM
Oct-14-25 05:01PM
Sep-30-25 05:01PM
Sep-12-25 08:19AM
06:10AM
Aug-28-25 11:30AM
Aug-12-25 05:30PM
08:56AM
Aug-08-25 05:01PM
Aug-05-25 08:18AM
Jul-31-25 03:25AM
Jul-29-25 07:00PM
06:15PM
05:11PM
(Associated Press Finance)
05:01PM
09:41AM
Jul-28-25 09:27AM
Jul-23-25 10:00AM
Jul-22-25 10:00AM
Jul-21-25 05:00PM
Jul-16-25 05:00PM
Jul-14-25 05:00PM
Jul-09-25 09:29AM
Jul-08-25 05:00PM
Jun-05-25 09:05AM
May-30-25 11:31AM
May-28-25 05:00PM
May-14-25 01:37PM
May-08-25 06:45AM
May-06-25 05:15PM
08:49AM
May-05-25 05:00PM
May-02-25 03:12AM
02:54AM
(Thomson Reuters StreetEvents)
May-01-25 07:48PM
Apr-30-25 07:30PM
06:50PM
05:47PM
(Associated Press Finance)
05:01PM
Apr-24-25 10:01AM
08:15AM
Apr-23-25 10:01AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MUSA OSAMA M SVP and CTO Sep 21 '26 Option Exercise 69.06 10,418 719,467 41,224 Sep 23 04:30 PM LAMPKIN ROBIN E. SVP, GC & Secretary Aug 11 '26 Option Exercise 74.58 1,806 134,691 6,825 Aug 12 04:30 PM MUSA OSAMA M SVP and CTO Jul 29 '26 Option Exercise 57.96 1,267 73,435 30,806 Jul 30 04:30 PM Assis Alessandra Faccin SVP and GM, Life Sciences Jul 27 '26 Option Exercise 66.38 3,215 213,412 9,099 Jul 29 04:30 PM MINICUCCI JAMES P. SVP and GM, Personal Care May 08 '26 Option Exercise 55.01 4,310 237,093 8,567 May 11 04:30 PM Kulkarni Ashish K Director Jan 21 '26 Option Exercise 0.00 2,113 0 2,113 Jan 22 04:30 PM NOVO GUILLERMO Chair of the Board and CEO Nov 17 '25 Option Exercise 49.60 6,122 303,651 143,412 Nov 19 04:30 PM Drury Eileen SVP and Chief HRO Nov 17 '25 Option Exercise 49.60 567 28,123 7,881 Nov 19 04:30 PM MUSA OSAMA M SVP and CTO Nov 17 '25 Option Exercise 49.60 976 48,410 29,875 Nov 19 04:30 PM MUSA OSAMA M SVP and CTO Nov 14 '25 Option Exercise 51.51 2,091 107,707 29,616 Nov 19 04:30 PM MUSA OSAMA M SVP and CTO Nov 13 '25 Option Exercise 53.10 1,393 73,968 28,002 Nov 19 04:30 PM RICHARDSON SAMUEL VP, Controller and PAO Nov 17 '25 Option Exercise 49.60 107 5,307 1,104 Nov 19 04:30 PM WHITAKER WILLIAM SVP, CFO & PFO Nov 17 '25 Option Exercise 49.60 107 5,307 2,082 Nov 19 04:30 PM LAMPKIN ROBIN E. SVP, Gen Counsel and Secrty. Nov 17 '25 Option Exercise 49.60 239 11,854 5,095 Nov 19 04:30 PM LAMPKIN ROBIN E. SVP, Gen Counsel and Secrty. Nov 14 '25 Option Exercise 51.51 1,276 65,727 5,237 Nov 17 09:43 PM LAMPKIN ROBIN E. SVP, Gen Counsel and Secrty. Nov 13 '25 Option Exercise 53.10 866 45,985 4,220 Nov 17 09:43 PM NOVO GUILLERMO Chair of the Board and CEO Nov 13 '25 Option Exercise 53.10 9,029 479,440 135,767 Nov 17 09:43 PM NOVO GUILLERMO Chair of the Board and CEO Nov 14 '25 Option Exercise 51.51 9,119 469,720 141,107 Nov 17 09:43 PM Drury Eileen SVP and Chief HRO Nov 14 '25 Option Exercise 51.51 1,297 66,808 7,917 Nov 17 09:38 PM Drury Eileen SVP and Chief HRO Nov 13 '25 Option Exercise 53.10 863 45,825 7,020 Nov 17 09:38 PM MINICUCCI JAMES P. SVP and GM, Personal Care Nov 14 '25 Option Exercise 51.51 1,225 63,100 4,640 Nov 17 09:38 PM MINICUCCI JAMES P. SVP and GM, Personal Care Nov 13 '25 Option Exercise 53.10 1,020 54,162 3,734 Nov 17 09:38 PM Assis Alessandra Faccin SVP and GM, Life Sciences Nov 13 '25 Option Exercise 53.10 1,340 71,154 6,286 Nov 17 09:37 PM Caceres Dago SVP & GM, Specialty Additives Nov 13 '25 Option Exercise 53.10 746 39,613 746 Nov 17 09:37 PM WHITAKER WILLIAM SVP, CFO & PFO Nov 14 '25 Option Exercise 51.51 356 18,338 2,083 Nov 17 09:36 PM WHITAKER WILLIAM SVP, CFO & PFO Nov 13 '25 Option Exercise 53.10 229 12,160 1,797 Nov 17 09:36 PM RICHARDSON SAMUEL VP, Controller and PAO Nov 14 '25 Option Exercise 51.51 228 11,744 1,066 Nov 17 09:35 PM RICHARDSON SAMUEL VP, Controller and PAO Nov 13 '25 Option Exercise 53.10 146 7,753 882 Nov 17 09:35 PM
Ashland, Inc. is an additives and specialty ingredients company, which engages in the provision of architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical products. It operates through the following segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. The Life Sciences segment is involved in pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films, and fine chemicals. The Personal Care segment consists of biofunctionals, microbial protectants, skin care, sun care, oral care, hair care, and household solutions. The Specialty Additives segment focuses on rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive, and various industrial markets. The Intermediates segment refers to production of 1,4 butanediol and related derivatives, including n-methylpyrrolidone. The company was founded in 1924 and is headquartered in Wilmington, DE.
Chairman & CEO Mr. Guillermo Novo
Senior VP Mr. William C. Whitaker C.F.A.
Senior VP & CTO Dr. Osama M. Musa Ph.D.
Senior VP & GM of Personal Care Mr. James P. Minicucci
Senior VP and GM of Life Sciences & Intermediates Ms. Alessandra Faccin Assis